Antimicrobial Resistance of Carbapenem-Resistant Enterobacteriaceae Isolates Between the Years of 2015-2018

Objective: The aim of this study was to determine the changes in carbapenem resistance of Enterobacteriaceae isolated from the samples sent to Ondokuz Mayıs University Hospital Medical Microbiology Laboratory in a 3-year period. Method: A total of 11264 Enterobacteriaceae strains isolated from the clinical samples sent to the laboratory between 2015-2018 were assessed. Clinical specimens were grown on 5% sheep blood agar and EMB agar media. Vitek MS (BioMérieux, France) automated system was used for the identification of bacterial species and Vitek2 Compact (BioMérieux, France) automated system for the determination of antibiotic susceptibility of bacteria. Results: Growth of different clinical specimens sent between 13 June 2015 and 13 June 2018 were evaluated retrospectively. Of the 11264 Enterobacteriaceae isolates, 518 (4.59%) were found to be carbapenem resistant. It was determined that the frequency of resistance was 4.62% in 2015 and 5.79% in 2018. When the distribution of the isolates according to the clinics and sample types was examined, the highest rate was identified in the internal medicine department with 71.62% and in urine samples with 52.32%. Conclusion: In our study carbapenem resistance was mostly identified in Klebsiella species. Amikacin susceptibility was found to be higher in carbapenemresistant isolates. It is important to monitor the resistance status with active surveillance in hospitals in order to determine the appropriate treatment option.

[1]  M. Castanheira,et al.  In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes , 2018, Antimicrobial Agents and Chemotherapy.

[2]  Hande Toptan,et al.  BİR İLAÇ MONOGRAFI : MEROPENEM-VABORBAKTAM , 2018 .

[3]  Güner Söyletir,et al.  Genişlemiş Spektrumlu Beta Laktamaz Üreten Enterobacteriaceae’larda Mutant Engelleme Konsantrasyonunun Saptanması , 2018 .

[4]  M. Shirley.  Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections , 2018, Drugs.

[5]  Yi-Wei Tang,et al.  Emergence of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae. , 2016, The Lancet. Infectious diseases.

[6]  L. Nabarro,et al.  Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  K. Kaye,et al.  Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections , 2015, Open forum infectious diseases.

[8]  M. Falagas,et al.  Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections , 2014, Emerging infectious diseases.

[9]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[10]  Michael Bell,et al.  Vital Signs: Carbapenem-Resistant Enterobacteriaceae , 2013, MMWR. Morbidity and mortality weekly report.

[11]  P. Nordmann,et al.  Carbapenem resistance in Enterobacteriaceae: here is the storm! , 2012, Trends in molecular medicine.

[12]  Thierry Naas,et al.  Global Spread of Carbapenemase-producing Enterobacteriaceae , 2011, Emerging infectious diseases.

[13]  Neil Woodford,et al.  What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. , 2011, International journal of antimicrobial agents.

[14]  W. Witte,et al.  Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. , 2010, International journal of medical microbiology : IJMM.

[15]  D. Raveh,et al.  Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreak. , 2010, The Journal of hospital infection.

[16]  M. Falagas,et al.  Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  B. Murray,et al.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.

[18]  Wonkeun Song,et al.  In vivo selection of carbapenem-resistant Klebsiella pneumoniae by OmpK36 loss during meropenem treatment. , 2009, Diagnostic microbiology and infectious disease.

[19]  D. Öğünç,et al.  Antimicrobial Resistance in Gram-Negative Hospital Isolates: Results of the Turkish HITIT-2 Surveillance Study of 2007 , 2009, Journal of chemotherapy.

[20]  D. Pillai,et al.  Klebsiella pneumoniae Carbapenemase, Canada , 2009, Emerging infectious diseases.

[21]  J. Campos,et al.  Emergence of imipenem resistance in clinical Escherichia coli during therapy. , 2008, International journal of antimicrobial agents.

[22]  P. Nordmann,et al.  Spread of OXA-48-Positive Carbapenem-Resistant Klebsiella pneumoniae Isolates in Istanbul, Turkey , 2008, Antimicrobial Agents and Chemotherapy.

[23]  N. Woodford,et al.  Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. , 2008, International journal of antimicrobial agents.

[24]  David L Paterson.  Resistance in gram-negative bacteria: enterobacteriaceae. , 2006, The American journal of medicine.

[25]  M. Falagas,et al.  Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria , 2005, BMC infectious diseases.

[26]  G. Jacoby,et al.  The new beta-lactamases. , 2005, The New England journal of medicine.

[27]  P. Nordmann,et al.  Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae , 2004, Antimicrobial Agents and Chemotherapy.

[28]  S. Ünal,et al.  The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  Gürhan Çiftçioğlu.  Tıbbi Mikrobiyoloji ve İmmünoloji , 2017 .

[30]  Gulay Yetkin,et al.  Kan Kültürlerinde Üreyen Escherichia coli’lerin Antibiyotik Duyarlılıkları, GSBL Oranları ve Hastane Birimlerine Göre Dağılımı , 2006 .